Clínic Barcelona
Research

Developed the first genomic test for personalized HER2+ breast cancer treatments

The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.

Related contents

Related news